Wegovy vs Zepbound (June 2026): SURMOUNT-5 Head-to-Head, Wegovy HD, & Cost Comparison
SURMOUNT-5 favored tirzepatide at the doses studied; it did not test Wegovy HD. Without insurance, the Wegovy pen costs $199 for the first two low-dose fills, then $349, and Zepbound vials cost $299 to $449 from LillyDirect.
By GLP-1 Picks, an independent comparison publication. Sources linked below. Our editorial policy.
Summarize this article with

In this article
- 01Does Wegovy or Zepbound work better for weight loss?
- 02How much do Wegovy and Zepbound cost?
- 03Does Wegovy or Zepbound have worse side effects?
- 04Are Wegovy and Zepbound covered by insurance?
- 05Which forms can you get?
- 06Who should choose Wegovy?
- 07Who should choose Zepbound?
- 08Which one should you choose?
- 09How does the dose go up?
- 10How do Wegovy and Zepbound work?
SURMOUNT-5 favored tirzepatide at the doses studied. Adults with obesity without diabetes received weekly tirzepatide 10 or 15 mg or semaglutide 1.7 or 2.4 mg for 72 weeks; mean weight loss was 20.2% versus 13.7%.
Semaglutide 7.2 mg was not tested.
In the August 7 manufacturer-direct check, NovoCare listed the Wegovy pen at $199/month for the first two low-dose fills, then $349/month at standard strengths ($399 for HD) and oral pill from $149/month, prescription required and dose-dependent.
LillyDirect listed Zepbound vials from $299/month, rising to $449 for higher doses under its stated refill terms. With eligible commercial insurance and a manufacturer savings card, either may cost as little as $25/month.
Both are FDA-approved for chronic weight management (Wegovy: June 2021, Zepbound: November 2023).
For eligible patients, Wegovy injection/tablets and Zepbound KwikPen only can cost $50 per monthly supply through the separate Medicare GLP-1 Bridge, outside ordinary Part D. Medicare's formulation and eligibility rules.
Which one fits you:
- •Weight-loss evidence: SURMOUNT-5 favored tirzepatide at the doses studied; it did not test Wegovy HD.
- •You want the lowest first fill from the maker: the Wegovy pen at $199 for the first two low-dose fills, against Zepbound's $299 starter vial. Wegovy then rises to $349 at standard strengths ($399 HD), while Zepbound follows its own dose and refill ladder.
- •You want to avoid needles: Wegovy, because it also comes as a daily pill. Zepbound is injection-only.
- •You rely on insurance: check your formulary rather than assuming either brand wins.
- •You're comparing compounded options: see cheapest GLP-1 providers or cheapest tirzepatide online. An advertised price does not show that a prescription meets 503A, 503B and state-law conditions.
See what each one costs and how to get it
Each page lists who prescribes it and what you pay. Your prescriber decides which one suits you.
Explore Wegovy access and costs →Does Wegovy or Zepbound work better for weight loss?
SURMOUNT-5 favored tirzepatide by 6.5 percentage points at the doses studied. This does not establish a comparison with semaglutide 7.2 mg.
SURMOUNT-5 was a Lilly-funded, open-label randomized trial of 751 adults with obesity without diabetes: weekly tirzepatide 10/15 mg versus semaglutide 1.7/2.4 mg for 72 weeks.
The pivotal solo trials, STEP 1 for Wegovy and SURMOUNT-1 for Zepbound, still provide useful dose-specific data but had different study populations and durations.
| SURMOUNT-5 Head-to-Head (NEJM) | STEP 1 (Wegovy solo) | SURMOUNT-1 (Zepbound solo) | |
|---|---|---|---|
| Active ingredient | Tirzepatide 10/15 mg vs semaglutide 1.7/2.4 mg | Semaglutide 2.4 mg | Tirzepatide 5/10/15 mg |
| Trial design | Head-to-head RCT, 751 adults | vs. placebo, 1,961 adults | vs. placebo, 2,539 adults |
| Trial duration | 72 weeks | 68 weeks | 72 weeks |
| Average weight loss | Zepbound: −20.2% | Wegovy: −13.7% | −14.9% | −15.0% (5mg) to −20.9% (15mg) |
| Waist circumference | −18.4 cm (Zep) vs −13.0 cm (Weg) | N/A | N/A |
Trial averages do not predict an individual result. The separate STEP 1 and SURMOUNT-1 results are not a head-to-head comparison.
FDA approved Wegovy HD (semaglutide 7.2mg injection) on March 20, 2026, the highest semaglutide dose available.
In Novo Nordisk-funded STEP UP, the 20.7% estimate at 72 weeks was an as-intended analysis in adults without diabetes; the primary treatment-policy estimate was 18.7%.
Tirzepatide was not studied. Wegovy HD is available via NovoCare from April 2026. See the Formulations section below.
Results are averages; individual outcomes vary based on genetics, diet, activity level, and dose tolerability.
For a month-by-month breakdown of semaglutide (Wegovy) results from the STEP trials, see our semaglutide before and after weight loss guide.
How much do Wegovy and Zepbound cost?
Between $25 and about $1,349 a month, depending on insurance, eligibility, product, and dose. Eligible commercially insured patients using a savings card may pay as little as $25/month.
In the August 7 cash-pay check, NovoCare listed the Wegovy pen at $199/month for the first two low-dose fills, then $349/month at standard strengths ($399 for HD) and pill from $149/month; LillyDirect listed Zepbound from $299/month with higher-dose pricing.
Pricing depends heavily on whether you have insurance, which manufacturer programs you use, and how you access the medication. Here's where each one stands:
| Wegovy | Zepbound | |
|---|---|---|
| List price | ~$1,349/mo | ~$1,086/mo |
| Current manufacturer self-pay | Pen $199 for first two low-dose fills, then $349 standard / $399 HD · pill from $149 (NovoCare) | $299-449/mo (LillyDirect vials, dose/refill terms apply) |
| Historical March 31 launch subscription | $249/mo (12-mo) · $279/mo (6-mo) · $329/mo (3-mo) | N/A |
| With insurance + savings card | As low as $25/mo | As low as $25/mo |
| Without insurance savings card | $499/mo | $499/mo |
| Medicare GLP-1 Bridge, if eligible | $50 per monthly supply; injection/tablets | $50 per monthly supply; KwikPen only |
| Oral option | Oral Wegovy $149/mo (starter): $299/mo (maintenance) | Not available |
Pricing timeline: Novo Nordisk launched a multi-month Wegovy subscription on March 31, 2026 through participating telehealth providers at $329/month (3-month), $279/month (6-month), and $249/month (12-month).
Those are historical launch terms. The current manufacturer-direct prices are in the table above.
For eligible Medicare beneficiaries, the separate GLP-1 Bridge includes Wegovy injection/tablets and Zepbound KwikPen only at $50 per approved monthly supply.
That is a drug copay, not a clinic subscription.
Telehealth alternatives with compounded options include Sprout Health compounded tirzepatide at $199 every 4 weeks (2025 FDA warning for misleading compounded-drug marketing) and Enhance MD compounded semaglutide or tirzepatide plans; advertised availability does not by itself establish the legal basis for a particular compounded prescription.
For a full breakdown, see cheapest GLP-1 providers or cheapest tirzepatide online.
Novo Nordisk's February 24 announcement sets US list prices for Wegovy, Ozempic and Rybelsus at $675/month from January 1, 2027.
It gives reductions of about 50% for Wegovy and 35% for Ozempic. This future list-price change does not affect direct-to-patient self-pay prices.
Compare the current manufacturer offers in the table, then check your prescribed product, insurance cost sharing and any clinic fees.
Does Wegovy or Zepbound have worse side effects?
These separate label rates do not establish which drug is easier to tolerate.
The Wegovy label reports 2.4 mg injection data from three adult placebo-controlled trials (n=2,116; up to 68 weeks).
The Zepbound label pools two trials (5/10/15 mg: n=630/948/941; up to 72 weeks). Both pools included adults with and without type 2 diabetes.
These are not Wegovy HD or oral-tablet rates.
| Adverse reaction | Wegovy 2.4 mg injection: separate label pool | Zepbound 5 / 10 / 15 mg: separate label pool |
|---|---|---|
| Nausea | 44% | 25% / 29% / 28% |
| Diarrhea | 30% | 19% / 21% / 23% |
| Vomiting | 24% | 8% / 11% / 13% |
| Constipation | 24% | 17% / 14% / 11% |
| Abdominal pain | 20% | 9% / 9% / 10% |
| Discontinued due to adverse reactions | 6.8% | 4.8% / 6.3% / 6.7% |
Lilly reports that SURMOUNT-5 was not powered to establish a safety or tolerability ranking.
For a breakdown of Zepbound label rates by assigned dose and questions for your prescriber, see our Zepbound side effects guide.
Both carry an FDA boxed warning about thyroid C-cell tumors (based on animal studies) and warnings for pancreatitis, gallbladder disease, and acute kidney injury.
Both are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.
Are Wegovy and Zepbound covered by insurance?
Coverage depends on the plan, formulation and indication. Commercial coverage varies.
The separate Medicare GLP-1 Bridge, outside ordinary Part D, includes Wegovy injection/tablets and Zepbound KwikPen at $50 per monthly supply for eligible, authorized patients.
Other covered medical uses follow the person's Part D plan. CMS explains the distinction.
Insurance coverage is one of the most important practical differences. Both face restrictions, but not the same ones:
- •Commercial insurance: Coverage varies dramatically by plan. Some insurers prefer Wegovy (because of Novo Nordisk's rebate deals), others prefer Zepbound (Lilly's contracts). Check your formulary or ask your provider to run a benefits check for both
- •Medicare: Basic Part D excludes weight-loss-only use. The separate Bridge can provide Wegovy injection/tablets or Zepbound KwikPen at $50 per monthly supply if eligible. The other Zepbound presentations are not included.
- •Prior authorization: Required by most insurers for both drugs. Typical requirements: BMI ≥30 (or ≥27 with comorbidity), documented failed diet/exercise attempts, and sometimes step therapy (trying cheaper medications first)
- •Wegovy cardiovascular indication: Wegovy has an additional FDA approval for cardiovascular risk reduction (based on the SELECT trial), which gives it coverage under some plans that exclude weight-loss-only medications
The cardiovascular indication is Wegovy's biggest insurance advantage.
If your insurer denies coverage for weight loss, your provider may be able to prescribe Wegovy for cardiovascular risk reduction if you meet the criteria; this pathway isn't available for Zepbound.
Which forms can you get?
Wegovy currently has more delivery options than Zepbound:
- •Wegovy injectable pen: 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, 2.4 mg, weekly injection with pre-filled auto-injector
- •Wegovy HD (7.2mg) injectable pen: FDA-approved March 20, 2026, Novo Nordisk's highest-dose semaglutide injection. STEP UP’s 20.7% estimate was an as-intended analysis, not a comparison with Zepbound. Available via NovoCare from April 2026
- •Oral Wegovy tablet: Approved December 2025, a semaglutide pill taken daily. Must be taken on an empty stomach with a small amount of water, then wait 30 minutes before eating. Available at starter doses through platforms like Ro
- •Zepbound injectable pen: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg, weekly injection with pre-filled auto-injector
- •Zepbound single-dose vials: Available through LillyDirect at lower prices than pen injectors, requires drawing into a syringe yourself
If you're needle-averse, Wegovy has a clear advantage with its oral tablet option. Zepbound is injection-only as of April 2026.
However, Foundayo (orforglipron), a different GLP-1 pill by Eli Lilly, was approved April 1, 2026 with no fasting requirements, giving needle-averse patients another Lilly option.
Who should choose Wegovy?
- •Your insurance covers Wegovy but not Zepbound: check your formulary first
- •You want an oral (pill) option and don't want injections
- •You have cardiovascular disease: Wegovy's SELECT trial data may help with insurance approval
- •You're already on Ozempic for diabetes and want to switch to the weight-loss dose
- •You prefer a longer track record: Wegovy has been on the market since June 2021
- •You are comparing manufacturer-direct floors: NovoCare listed the Wegovy pen at $199/mo for the first two low-dose fills, then $349/mo at standard strengths ($399 for HD) in the August 7 check, below LillyDirect's $299/mo Zepbound starter vial; confirm your dose and checkout total before deciding
Who should choose Zepbound?
- •You want to discuss SURMOUNT-5’s findings for the doses studied with your prescriber.
- •You're paying out of pocket and want the most weight loss per the head-to-head trial: LillyDirect vials start at $299/mo
- •For weight management, the Zepbound label lists 5, 10 or 15 mg once weekly as maintenance doses. Your prescriber selects the dose based on response and tolerability.
- •Your insurance covers Zepbound or has it as a preferred formulary option
Which one should you choose?
SURMOUNT-5 favored tirzepatide at its tested doses; semaglutide 7.2 mg was not included, and LillyDirect vials start at $299/mo if you pay cash.
The Wegovy pen costs less for the first two low-dose fills ($199), then $349 at standard strengths.
If insurance coverage is your top priority, check your formulary for both drugs and go with whichever is covered.
Wegovy's cardiovascular indication gives it an edge for insurance approval in cases where weight-loss-only coverage is denied.
If you hate needles, Wegovy is your only option among these two (oral tablet available). You could also consider Foundayo, a daily GLP-1 pill with no fasting requirements.
Both are effective, FDA-approved medicines when combined with diet and exercise. Trial averages cannot predict an individual’s response or tolerability.
Not sure which provider to use? Check our ranked list of GLP-1 telehealth providers or take the match quiz to get a personalized recommendation.
You can also use the cost calculator to estimate what you'd actually pay based on your insurance and medication preference.
How does the dose go up?
These are once-weekly injection schedules for adult weight management, not oral Wegovy or a personal dosing plan. Both medicines start at low doses; your prescriber guides any increases based on response and tolerability.
| Stage | Wegovy injection | Zepbound injection |
|---|---|---|
| Starting dose | 0.25 mg once weekly for 4 weeks | 2.5 mg once weekly for 4 weeks; not a maintenance dose |
| Escalation | 0.5 mg, 1 mg, then 1.7 mg once weekly, with 4 weeks at each step; an increase may be delayed if not tolerated | Increase to 5 mg after 4 weeks; further increases are in 2.5 mg steps after at least 4 weeks at the current dose |
| Adult weight-management maintenance | 1.7 mg or 2.4 mg once weekly; 2.4 mg is recommended | 5 mg, 10 mg or 15 mg once weekly |
| Higher-dose Wegovy | For adults needing additional weight reduction, the prescriber may increase to 7.2 mg once weekly after at least 4 weeks tolerating 2.4 mg | Not applicable |
The Wegovy label and Zepbound label guide dose selection by response and tolerability.
Zepbound's 7.5 mg and 12.5 mg doses are escalation steps, rather than the listed maintenance options for weight management. Reaching the highest dose is not a requirement for every patient.
How do Wegovy and Zepbound work?
Wegovy (semaglutide) is a GLP-1 receptor agonist. It mimics the natural GLP-1 hormone your gut produces after eating, which slows gastric emptying, reduces appetite, and signals fullness to the brain.
It's the same active ingredient as Ozempic (approved for diabetes at a lower dose).
Zepbound (tirzepatide) is a dual GIP/GLP-1 receptor agonist. It does everything semaglutide does, but also activates GIP (glucose-dependent insulinotropic polypeptide) receptors.
GIP affects fat storage, energy expenditure, and appetite through different pathways than GLP-1 alone. This dual mechanism is believed to explain Zepbound's higher average weight loss in trials.
Tirzepatide is the same active ingredient as Mounjaro (approved for Type 2 diabetes). Zepbound is the weight-loss-specific brand approved in November 2023.
Medical disclaimer: This article is general information, not medical advice. Talk to a licensed clinician before you start, stop or change any medication. Prices and rules can change after the date we checked them.
Affiliate disclosure: Some links in this article are affiliate links. If you join a program through one, we may earn a commission at no extra cost to you.
Medicare & GLP-1
Medicare GLP-1 Coverage Guide
On Medicare? From July 1, 2026, the Medicare GLP-1 Bridge sets a $50 monthly copay for Wegovy, Zepbound and Foundayo. Our guide explains who qualifies and what it covers.
Read the Medicare guide →What the doctors say
Quotes from named doctors and medical bodies, each linked to where they said it. We did not ask for them, and they do not endorse any provider.
“People with overweight or obesity have individual preferences, and with oral semaglutide as a potential new treatment option, more of those who are not on treatment today may consider starting GLP-1 treatment.”
“We now have medicines that not only reduce heart attacks, strokes, and peripheral arterial disease, but also simultaneously lead to meaningful weight loss, which in turn lowers the risk of many weight-related conditions. These treatments also improve patients' quality of life in a meaningful way, making this a genuine win, win.”
“It's the first time that we have seen this magnitude of weight loss compared to current medications on the market for obesity. It's 1.5 to 2.5 times more effective than currently available drugs.”
Quotes are general medical commentary about GLP-1 medications, independently sourced and not solicited by GLP-1 Picks. They are not an endorsement of any provider, our provider scores are set solely by our published methodology.